title: [Correlation of insulin-like growth factor-1 (IGF-1) to angiogenesis of breast cancer in IGF-1-deficient mice].
abstract: OBJECTIVE
  Insulin-like growth factors (IGFs) play important roles in the development and progression of tumors. But the mechanism of tumorigenesis in relation to IGF-1 is unclear yet. This study was to explore the correlation of circulating IGF-1 level to the angiogenesis of breast cancer in IGF-1-deficient mice.
  
  
  METHODS
  The liver-specific IGF-1-deficient (LID) mice and control mice were injected with 7,12-dimethybenz(a)anthracene (DMBA) to develop breast cancer. Ginsenoside Rg3 was used to intervene tumor growth. The occurrence rates of breast cancer were compared. The expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) was detected by immunohistochemistry.
  
  
  RESULTS
  The occurrence rate of breast cancer was 66.67% in untreated control mice, 33.33% in untreated LID mice, 36.00% in Rg3-treated control mice, and 12.00% in Rg3-treated LID mice. The tumor size was (0.79+/-0.20) cm in untreated control mice, (0.37+/-0.08) cm in untreated LID mice, (0.32+/-0.08) cm in Rg3-treated control mice, and (0.15+/-0.05) cm in Rg3-treated LID mice. The average light density and positive rate of VEGF were the highest in untreated control mice (0.34+/-0.10 and 0.04+/-0.02, P<0.05), and the lowest in Rg3-treated LID mice (0.13+/-0.03 and 0.01+/-0.00, P<0.05). The MVD was 31.9+/-5.3 in untreated control mice, 26.8+/-4.9 in untreated LID mice, 20.1+/-4.9 in Rg3-treated control mice, and 14.4+/-4.9 in Rg3-treated LID mice.
  
  
  CONCLUSIONS
  Circulating IGF-1 plays a role in the onset and development of breast cancer. Degrading serum IGF-1 level could inhibit angiogenesis and growth of breast cancer. Rg3 could promote this effect.
authors.affiliation: Department of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, PR China.
authors.forename: Hong-Bo
authors.initials: HB
authors.lastname: Tang
authors.forename: Yu-Ping
authors.initials: YP
authors.lastname: Ren
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.forename: Shi-Hui
authors.initials: SH
authors.lastname: Ma
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Yi-Ping
authors.initials: YP
authors.lastname: Wu
mesh_terms: D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D005260:Female; D036145:Ginsenosides / Q000494:pharmacology*; D007334:Insulin-Like Growth Factor I / Q000172:deficiency* / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D055806:Microvessels / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000209:etiology*; D011897:Random Allocation; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D036145:Ginsenosides; D042461:Vascular Endothelial Growth Factor A; C519530:insulin-like growth factor-1, mouse; C097367:ginsenoside Rg3; D015127:9,10-Dimethyl-1,2-benzanthracene; D007334:Insulin-Like Growth Factor I